The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Higginbotham, E J ^a   Diestelhorst, M ^b   Pfeiffer, N ^c   Rouland, J F ^d   Alm, A ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIV LILLE   (France)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Prostaglandin analog; Timolol

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

AQUEOUS HUMOR FLOW; AREA UNDER THE CURVE; CELL DENSITY; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CORNEA THICKNESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EYE COLOR; EYE IRRITATION; EYELASH; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GLAUCOMA; HUMAN; HYPEREMIA; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DRUG THERAPY, COMBINATION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MYDRIATICS; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SAFETY;

EID: 0036669663     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00295-3     Document Type: Review

References (25)

1. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 102:1995;1743-1752.
2. Alm A., Widengard I., Kjellgren D.et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 79:1995;12-16.
3. Boyle J.E., Ghosh K., Gieser D.K., Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 105:1998;1945-1951.
4. Bucci M.G. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group J Glaucoma. 8:1999;24-30.
5. Camras C.B., Alm A., Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 103:1996;1916-1924.
6. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group Ophthalmology. 103:1996;138-147.
7. Diestelhorst M., Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 236:1998;577-581.
8. Emmerich K.H. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 238:2000;19-23.
9. Fristrom B., Nilsson S.E. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 111:1993;662-665.
10. Hayreh S.S., Podhajsky P., Zimmerman M.B. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 128:1999;301-309.
11. Higginbotham EJ, Stiles MC, Dubiner HB, Feldman RM: The efficacy of latanoprost-timolol combination in patients with either POAG or ocular hypertension: One-year results. Arch Ophthalmol In press.
12. Hoyng P.F., Rulo A., Greve E. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol. 41(Suppl):1997;593-598.
13. Kent A.R., Vroman D.T., Thomas T.J.et al. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. J Glaucoma. 8:1999;257-262.
14. Kimal Arici M., Topalkara A., Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 22:1998;37-42.
15. Lass J.H., Eriksson G.L., Osterling L., Simpson C.V. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: A double-masked, randomized, one-year study Ophthalmology. 108:2001;264-271.
16. Maus T.L., Nau C., Brubaker R.F. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 117:1999;586-591.
17. Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 26:1995;233-236.
18. Pfeiffer N., the GLFCSG A comparison of the FC of L and T with its individual components in patients with glaucoma or OHTN. Invest Ophthalmol Vis Sci. 41(Suppl):2000;S754. [abstract].
19. Rulo A.H., Greve E.L., Hoyng P.F. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology. 104:1997;1503-1507.
20. Rulo A.H., Greve E.L., Hoyng P.F. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 78:1994;899-902.
21. Stewart W.C., Day D.G., Sharpe E.D.et al. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol. 128:1999;692-696.
22. Stewart W.C., Sharpe E.D., Day D.G.et al. Comparison of the efficacy and safety of latanoprost ;0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta- adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 16:2000;251-259.
23. Villumsen J., Alm A. Effect of the prostaglandin F2a analogue PhXA41 in eyes treated with pilocarpine and timolol. Invest Ophthalmol Vis Sci. 33(Suppl):1992;1248. [abstract].
24. Watson P.G. Latanoprost. Two years experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 105:1998;82-87.
25. Widengard I., Maepea O., Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol. 82:1998;404-406.